DocWire News Editors

DocwireNews

New research presented at the ESC Congress 2020 in Sophia Antipolis, France, suggests that the antianginal agent trimetazidine given after successful percutaneous coronary intervention (PCI) was not effective at reducing adverse outcomes.Researchers for the ATPCI study, published simultaneously in <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31790-6/fulltext">The Lancet</a>, conducted a randomized, double-blind, placebo-controlled study that included 6,007 patients who had either elective PCI for stable angina or urgent PCI for unstable angina or <a href="https://www.docwirenews.com/abstracts/cardiology-abstracts/incidence-characteristics-and-outcomes-in-very-young-patients-with-st-segment-elevation-myocardial-infarction/">non-STEMI</a> less than 30 days prior to randomization. Patients were randomly assigned to either oral trimetazidine 35 mg modified-release twice daily (n=2,998) or to a matched placebo (n=3,009). The primary outcome of interest was composite cardiac death; hospital admission for <a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/can-a-selfie-help-detect-coronary-artery-disease/">cardiac</a> event; recurrence or persistence of angina requiring an addition/switched/increased does of at least one antianginal drug; or persistent recurrent angina requiring coronary angiography. Median follow-up was 47.5 months.According to the results, after follow-up, there was no significant difference in the occurrence of the primary study endpoint in the trimetazidine group compared to the placebo group (23.7% vs. 23.3%, respectively; P=0.73). There were also no significant differences in the incidences of components of the composite endpoint between groups. The researchers reported similar results when patients were categorized by either elective or urgent PCI. A total of 1,219 (40.9%) in the treatment arm and 41.1% in the placebo arm showed serious treatment-emergent adverse events. The frequencies of adverse events of interest were also similar between the study cohorts.&ldquo;Our results show that the routine use of oral trimetazidine 35 mg twice daily over several years in patients receiving optimal medical therapy, after successful PCI, does not influence the recurrence of angina or the outcome; these findings should be taken into account when considering the place of trimetazidine in clinical practice,&rdquo; the authors wrote in the abstract. &ldquo;However, the long-term prescription of this treatment does not appear to be associated with any statistically significant safety concerns in the population studied.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/ESCCongress?src=hash&amp;ref_src=twsrc%5Etfw">#ESCCongress</a> <a href="https://t.co/qJR8KeXNS9">https://t.co/qJR8KeXNS9</a>
&mdash; Silvia Castelletti (@SilCastelletti) <a href="https://twitter.com/SilCastelletti/status/1300684313835511809?ref_src=twsrc%5Etfw">September 1, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
&#128161; The routine use of <a href="https://twitter.com/hashtag/trimetazidine?src=hash&amp;ref_src=twsrc%5Etfw">#trimetazidine</a> 35 mg twice daily over several years in patients receiving optimal medical therapy, after successful PCI, does not influence the recurrence of angina or the outcome&hellip; Was anyone still using it?<a href="https://twitter.com/hashtag/ESCCongress?src=hash&amp;ref_src=twsrc%5Etfw">#ESCCongress</a> <a href="https://twitter.com/TheLancet?ref_src=twsrc%5Etfw">@TheLancet</a> <a href="https://t.co/9HqPYhPryC">https://t.co/9HqPYhPryC</a> <a href="https://t.co/ITBPhsh37B">pic.twitter.com/ITBPhsh37B</a>
&mdash; Fernando de la Gu&iacute;a (@Cardio_delaGuia) <a href="https://twitter.com/Cardio_delaGuia/status/1300558756007284736?ref_src=twsrc%5Etfw">August 31, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
ATPCI: 6000 pats w/ elective PCI or PCI for UAP/NSTEMI within 30 days were randomized to &ndash; trimetazidine 35 mg 2x/d &ndash; placebo
No difference in the 1&deg; combined endpoint (CV death, hospitalization, angina) or any endpoint alone.<a href="https://twitter.com/hashtag/ESCCongress?src=hash&amp;ref_src=twsrc%5Etfw">#ESCCongress</a> <a href="https://twitter.com/TheLancet?ref_src=twsrc%5Etfw">@TheLancet</a> <a href="https://t.co/9qLT919Zk8">https://t.co/9qLT919Zk8</a> <a href="https://t.co/iDh4fmQSH1">pic.twitter.com/iDh4fmQSH1</a>
&mdash; Konstantin Krychtiuk (@krychtiukmd) <a href="https://twitter.com/krychtiukmd/status/1300363965609005056?ref_src=twsrc%5Etfw">August 31, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Latest News

Trimetazidine Does Not Improve Outcomes Post-Revascualrization

Interventional Cardiology

New research presented at the ESC Congress 2020 in Sophia Antipolis, France, suggests that the antianginal agent trimetazidine given after successful percutaneous coronary ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe